CN116874590A - Recombinant III type collagen and preparation method thereof - Google Patents
Recombinant III type collagen and preparation method thereof Download PDFInfo
- Publication number
- CN116874590A CN116874590A CN202311032714.6A CN202311032714A CN116874590A CN 116874590 A CN116874590 A CN 116874590A CN 202311032714 A CN202311032714 A CN 202311032714A CN 116874590 A CN116874590 A CN 116874590A
- Authority
- CN
- China
- Prior art keywords
- collagen
- recombinant
- type iii
- iii type
- iii collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 57
- 108010035532 Collagen Proteins 0.000 title claims abstract description 57
- 229920001436 collagen Polymers 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 42
- 102000001187 Collagen Type III Human genes 0.000 claims description 39
- 108010069502 Collagen Type III Proteins 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 8
- 238000010353 genetic engineering Methods 0.000 abstract description 7
- 239000002773 nucleotide Substances 0.000 abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 abstract description 6
- 210000002950 fibroblast Anatomy 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 238000005457 optimization Methods 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000012474 protein marker Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- -1 cell adhesion and differentiation Diseases 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The application discloses recombinant III type collagen and a preparation method thereof, and relates to the technical field of genetic engineering. The amino acid sequence of the recombinant III type collagen is shown as SEQ ID NO. 3. The recombinant III type collagen is obtained by taking a nucleotide sequence of human III type collagen as a template for design and optimization, and has good biocompatibility, low toxicity and low immunogenicity compared with natural III type collagen. According to the experimental result of cell proliferation promotion, the recombinant III type collagen provided by the application can obviously promote proliferation and migration of fibroblasts, and has wide application prospects in industries such as biological medicine, cosmetics, skin care products, food and the like.
Description
Technical Field
The application relates to the technical field of genetic engineering, in particular to recombinant III-type collagen and a preparation method thereof.
Background
Collagen is the most abundant protein in mammals, accounting for about 25% of the total protein content in humans. Collagen, which is an adhesive substance of connective tissue, plays an important role in maintaining normal physiological functions of cells, tissues, and organs, has been demonstrated to be directly or indirectly involved in promotion of cell adhesion and differentiation, which are associated with embryonic development and regeneration control.
Collagen is a major structural protein in the extracellular matrix and connective tissue, the basic structure of which consists of three helical subunits: two α1 (I) chains and one α2 (I) chain. At least 28 different types of collagen are currently known, all of which contain three-ply helical segments of similar structure, each differing by breaking the segments of the three-ply helical structure and folding into other types of three-dimensional structures. Among them, type I, type II and type III collagens occupy 80% of the collagen content in the body.
Type III collagen plays an important role in the regulation of the organization structure and function of the extracellular matrix, and is involved in many physiological and pathological processes, including structural support, cell adhesion and differentiation, inflammation-related pathological processes, and association with certain diseases. Type III collagen, an extracellular matrix protein synthesized by cells as procollagen, is found as a major structural component of hollow organs such as large blood vessels, uterus and intestines. Other functions of type III collagen include interactions with platelets in the coagulation cascade, which is also an important signaling molecule in wound healing.
Collagen has biodegradability, good biocompatibility and low immunogenicity; can promote proliferation and adhesion of cells; in addition, the collagen can form collagen fibers, has certain mechanical properties, is a good biological material, and can be widely used. The collagen is mainly used as collagen-based biological materials in medicine, such as heart valves, vascular repair, soluble collagen periodontal repair, burn repair, collagen hemostatic, gelatin, artificial skin, immobilized enzyme carriers, capsules, collagen membranes and the like.
At present, most of collagen used in the medicine industry, the food industry and the cosmetic industry is obtained by extracting pigskin, fish skin and cowhells by an acid, alkali and enzyme method. Collagen extracted by this method has many drawbacks that are difficult to overcome: (1) has virus hidden trouble; (2) Has certain antigenicity, and can lead to immune rejection reaction when entering the organism; (3) the extraction method is seriously polluted; (4) raw materials are limited in source.
The recombinant collagen is an expression engineering bacterium which is constructed by utilizing a genetic engineering technology and contains a full-length gene or a partial fragment gene of the collagen, the collagen is synthesized by the engineering bacterium, and finally, the high-purity recombinant collagen is obtained by adopting a specific purification process. The recombinant collagen produced by adopting the genetic engineering technology has higher controllability, consistency and high purity, can be produced in a large scale and has better biocompatibility; has wide application prospect, including the fields of tissue engineering, drug delivery systems, biomedical research and the like.
Disclosure of Invention
The technical problem to be solved by the application is to use a genetic engineering technology to recombine and express a new III type collagen and a preparation method of the recombined III type collagen.
In order to solve the problems, the application provides the following technical scheme:
in a first aspect, the present application provides a recombinant type III collagen, wherein the amino acid sequence of the recombinant type III collagen is shown as SEQ ID No.3, or has an amino acid sequence with 1 or more amino acids added, substituted, deleted, and the like compared to the amino acid sequence shown as SEQ ID No.3, which retains a similar effect.
The technical scheme is that the amino acid sequence of the recombinant III type collagen comprises 2-10 repeated SEQ ID NO:3.
further, the application provides a nucleic acid molecule which codes for the recombinant type III collagen.
The further technical scheme is that the sequence of the nucleic acid molecule is shown as SEQ ID NO. 4.
The application also provides a vector comprising the nucleic acid molecule.
The application also provides a host cell comprising said collagen or said nucleic acid molecule or said vector.
By host cell is meant any cell type that is susceptible to transformation, transfection, transduction, etc. by a nucleic acid construct or expression vector comprising a polynucleotide of the application. "host cell" encompasses any progeny of a parent cell that is not exactly identical to the parent cell due to mutations that occur during replication. The host cell may be any cell useful in the production of recombinant humanized collagen of the present application. To produce recombinant collagen, nucleic acid encoding recombinant collagen may be isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acids can be readily isolated and sequenced using conventional techniques (e.g., by using oligonucleotide probes that are capable of specifically binding to genes encoding recombinant collagen). The host cell refers to a cell into which exogenous nucleic acid has been introduced, including the progeny of such a cell. Host cells include transformants and transformed cells, including primary transformed cells and progeny derived therefrom, regardless of the number of passages. The offspring may not be identical in nucleic acid content to the parent cell, but may contain mutations. Methods for introducing vectors into host cells are well known, for example, using electrotransformation to introduce vectors into host cells, and may also be transfection, microinjection techniques, gene gun techniques, liposome-mediated methods, and the like. The host cell is a prokaryotic cell or a eukaryotic cell. The host cell is selected from any one of pichia pastoris, saccharomyces cerevisiae, escherichia coli and bacillus subtilis. Preferably, the prokaryotic cell is escherichia coli; preferably, the eukaryotic cell is pichia pastoris.
The application also provides a method for preparing the recombinant type III collagen, which comprises the following steps:
and expressing the recombinant III type collagen by using the host cell, and then separating and purifying to obtain the recombinant III type collagen.
The application also provides the application of the recombinant type III collagen according to the first aspect, or the recombinant type III collagen encoded by the nucleic acid molecule, or the recombinant type III collagen produced by the host cell in preparing food, cosmetics or pharmaceutical products.
The application also provides a composition comprising the recombinant type III collagen according to the first aspect, or the recombinant type III collagen encoded by the nucleic acid molecule, or the recombinant type III collagen produced by the host cell.
The application also provides application of the composition in preparing food, cosmetics or medical products.
Compared with the prior art, the application has the following technical effects:
the application uses the nucleotide sequence of human III type collagen as a template, utilizes the genetic engineering technology to construct a new recombinant III type collagen, synthesizes the recombinant III type collagen by genetic engineering bacteria, and obtains high-purity recombinant collagen through a purification process. According to the experimental result of cell proliferation promotion, the recombinant III type collagen provided by the application can obviously promote the proliferation of fibroblasts, and has wide application prospects in the industries of biological medicines, cosmetics, skin care products, foods and the like.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for the description of the embodiments will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present application, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows SDS-PAGE electrophoresis of recombinant type III collagen HC8 prepared in the embodiment of the application at different induction expression times; in the figure, band 1, protein Marker standard, band 2, uninduced expressed bacteria, band 3: inducing the expression bacteria for 1h, inducing the expression bacteria for 2h in a band 4, and inducing the expression bacteria for 4h in a band 5.
FIG. 2 shows the SDS-PAGE of recombinant type III collagen purified according to the example of the present application; in the figure, band 1 is a protein Marker standard, and band 2 is purified recombinant type III collagen HC8.
FIG. 3 shows the results of the proliferation rate of recombinant type III collagen HC8 according to the present application.
Detailed Description
The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, in which like reference numerals represent like components. It will be apparent that the embodiments described below are only some, but not all, embodiments of the application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
It should be understood that the terms "comprises" and "comprising," when used in this specification and the appended claims, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
It is also to be understood that the terminology used in the description of the embodiments of the application herein is for the purpose of describing particular embodiments only and is not intended to be limiting of embodiments of the application. As used in the specification of the embodiments of the application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
The main materials related to the embodiment of the application are as follows: plasmid pET-30a (Merck), host bacterium E.coli BL21 (DE 3) (Merck), protein Marker were purchased from Thermo Fisher Scientific company, ni Sepharose TM 6Fast Flow was purchased from Bozuron (Shanghai) Biotechnology Co., ltd, and CCK-8 kit was purchased from Biyun Biotechnology Co., ltd.
Buffer used for Ni-NTA affinity chromatography, equilibration buffer 20mmol/L Tris-HCl,0.25mol/LNaCl,10mmol/L imidazole (pH 8.0), elution buffer A20 mmol/L Tris-HCl,0.25mol/LNaCl,40mmol/L imidazole (pH 8.0), elution buffer B20 mmol/L Tris-HCl,0.25mol/LNaCl,300mmol/L imidazole (pH 8.0).
Example 1: recombinant III type collagen expression vector construction
The application takes the nucleotide sequence of human III type collagen as a (NM_ 000090.3) template, analyzes the composition and structure of the sequence, screens out a specific peptide on the human III type collagen by analyzing the stability of the peptide and the receptor binding capacity on cells, and the like, wherein the amino acid sequence of the peptide is SEQ ID NO:1. the nucleotide sequence of the peptide fragment is shown as SEQ ID NO:2.
the peptide segment is used as a basic structural unit for optimization design to obtain recombinant human III type collagen, which is marked as HC8 and consists of 503 amino acids, and the amino acid sequence is shown as SEQ ID NO:3. The nucleotide sequence of the recombinant human III type collagen HC8 is shown as SEQ ID NO: 4.
And optimizing the designed nucleotide sequence of the recombinant III type collagen HC8 according to the codon preference of the escherichia coli, adopting total gene synthesis of the DNA sequence of the recombinant III type collagen, and constructing the DNA sequence on a pET-30a expression vector, wherein the recombinant plasmid vector is named pET-30a-HC8.
The DNA sequence of the recombinant III type collagen subjected to codon optimization is shown as SEQ ID NO: shown at 5.
Example 2: expression and purification of recombinant type III collagen HC8
(1) Preparation of recombinant type III collagen HC8 expressing strain:
(1) competent cells of E.coli BL21 (DE 3) were prepared.
(2) The expression vector pET-30a-HC8 was transformed into competent cells of E.coli BL21 (DE 3) at 42℃for 90s by heat shock.
(2) Recombinant type III collagen HC8 induced expression and solubility analysis:
inoculating the expression strain pET-30a-HC8 obtained in the step (1) into 100mL of LB medium containing 50 mug/mL kanamycin content, culturing at 37 ℃ and 200rpm, adding IPTG when OD600 = 0.8, carrying out induction expression for 4h at 37 ℃, and centrifuging at 8000g and 4 ℃ for 10min to collect thalli. The cells were resuspended in PBS buffer, homogenized and disrupted at high pressure (1000 bar), centrifuged at 18000g at 4℃for 60min, and the supernatant and pellet were respectively subjected to subsequent SDS-PAGE (5% gel concentrate, 12% gel isolate) and Westernblot analysis.
(3) Recombinant III type collagen HC8 shake flask fermentation and purification
Inoculating recombinant type III collagen HC8 expression strain obtained in the step (1) into 2L LB culture medium with kanamycin content of 50 mug/mL respectively, and carrying out shake flask fermentation and induction according to the expression conditions. Centrifuging at 4 ℃ for 6000 Xg for 10min to collect thalli, and precipitating the thalli according to the volume ratio of 1:12 ratio resuspended in Ni-NTA affinity chromatography equilibration buffer and the cells were broken up homogeneously at high pressure (1000 bar). Supernatant was collected by centrifugation at 25000 Xg for 60min at 4 ℃.
The bacterial cell disruption and centrifugation supernatant is purified by Ni-NTA affinity chromatography, and the specific steps are as follows: loading the supernatant onto a Ni-NTA affinity chromatographic column with a bed volume of 10mL, a flow rate of 5mL/min, washing back to a base line with an equilibrium buffer solution, a flow rate of 5mL/min, eluting the protein impurity with an elution buffer solution A, and eluting the target protein with an elution buffer solution B; purified recombinant type III collagen HC8 is subjected to SDS-PAGE electrophoresis to identify the purity of the purified collagen. The results are shown in FIGS. 1-2.
Example 3: evaluation of recombinant type III collagen HC8 proliferation promoting Activity
Taking BALB/c 3T3 cells (mouse embryo fibroblasts) in logarithmic growth phase (purchased from Shanghai cell bank of China academy of sciences) and inoculating into 96-well cell culture plate with an inoculating density of 1×10 5 100 mu L of each well is placed in each volume of the solutionIn a carbon dioxide cell incubator at 37 ℃ and 5% CO 2 Culturing for 24h conventionally. The culture was continued for 12h with a serum-free medium. Then 100. Mu.L of serum-free culture solution or 100. Mu.L of recombinant type III collagen HC8 sample solution was added thereto, and the culture was continued for 24 hours. Each solution was 400. Mu.g/mL and the solution was sterilized by filtration through a 0.22 μm filter. After further culturing for 24 hours, the culture broth was discarded, 100. Mu.L of CCK-8 (available from Shanghai Biotechnology Co., ltd.) diluted 10-fold with serum-free culture broth was added to each well, and the mixture was placed in a cell incubator at 37℃with 5% CO 2 And taking out after incubation for 2 hours.
Reading the absorbance values of the 96-well plate at 450nm and 630nm by using an enzyme-labeled instrument, measuring absorbance at 450nm by taking 630nm as a reference wavelength, recording the measurement result, and obtaining the relative proliferation rate according to the following formula:
relative proliferation% = (sample OD-control)/(control OD-medium OD).
In the test, a blank control group is added with an equivalent serum-free culture solution, a control group is a commercially available recombinant type III collagen sample solution, an experimental group is added with 100 mu L of the recombinant type III collagen sample solution, and 3 parallel samples are taken in each group.
As shown in fig. 3, the experimental results indicate that: under the condition of the concentration of 1 mug/mL, the mobility of the collagen of the control group and the recombinant type III collagen HC8 relatively promote the fibroblasts is 12.95% and 26.64%, respectively, and compared with the control group, the recombinant type III collagen HC8 provided by the application can obviously promote the proliferation of the fibroblasts.
In the foregoing embodiments, the descriptions of the embodiments are focused on, and for those portions of one embodiment that are not described in detail, reference may be made to the related descriptions of other embodiments.
While the application has been described with reference to certain preferred embodiments, it will be understood by those skilled in the art that various changes and substitutions of equivalents may be made and equivalents will be apparent to those skilled in the art without departing from the scope of the application. Therefore, the protection scope of the application is subject to the protection scope of the claims.
Claims (10)
1. The recombinant type III collagen is characterized in that the amino acid sequence of the recombinant type III collagen is shown as SEQ ID NO.3 or has an amino acid sequence with 1 or more amino acids added, substituted and deleted compared with the amino acid sequence shown as SEQ ID NO. 3.
2. A nucleic acid molecule encoding the recombinant type III collagen of claim 1.
3. The nucleic acid molecule of claim 2, wherein the sequence of the nucleic acid molecule is set forth in SEQ ID No. 4.
4. A vector comprising the nucleic acid molecule of claim 2 or 3.
5. A host cell comprising the collagen of claim 1 or the nucleic acid molecule of claim 2 or 3 or the vector of claim 4.
6. The host cell of claim 5, wherein the host cell is a prokaryotic cell or a eukaryotic cell.
7. A method of preparing the recombinant type III collagen of claim 1, comprising the steps of:
expressing the recombinant type III collagen using the host cell of any one of claims 5-6, followed by isolation and purification.
8. Use of the recombinant type III collagen according to claim 1, or the recombinant type III collagen encoded by the nucleic acid molecule of claim 2 or 3, or the recombinant type III collagen produced by the host cell of any one of claims 5-6, in the preparation of a food, cosmetic or pharmaceutical product.
9. A composition comprising the recombinant type III collagen according to claim 1, or the recombinant type III collagen encoded by the nucleic acid molecule of claim 2 or 3, or the recombinant type III collagen produced by the host cell of any one of claims 5-6.
10. Use of a composition according to claim 9 for the preparation of a food, cosmetic or pharmaceutical product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311032714.6A CN116874590B (en) | 2023-08-16 | 2023-08-16 | Recombinant III type collagen and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311032714.6A CN116874590B (en) | 2023-08-16 | 2023-08-16 | Recombinant III type collagen and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116874590A true CN116874590A (en) | 2023-10-13 |
| CN116874590B CN116874590B (en) | 2024-06-07 |
Family
ID=88270087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311032714.6A Active CN116874590B (en) | 2023-08-16 | 2023-08-16 | Recombinant III type collagen and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116874590B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117986355A (en) * | 2024-04-03 | 2024-05-07 | 江苏亨瑞生物医药科技有限公司 | Recombinant humanized III type collagen and preparation method and application thereof |
| CN118909094A (en) * | 2024-08-09 | 2024-11-08 | 上海兰之美雅化妆品有限公司 | Recombinant III type collagen Yves-Col3 with anti-aging effect and preparation method and application thereof |
| CN119431561A (en) * | 2025-01-13 | 2025-02-14 | 江苏亨瑞生物医药科技有限公司 | Method for fermenting and recombining humanized collagen by using escherichia coli and application of method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110092835A (en) * | 2018-01-30 | 2019-08-06 | 上海惠盾生物技术有限公司 | A kind of GLP-1 analog-COL3A1 fusion protein |
| CN111944057A (en) * | 2020-07-23 | 2020-11-17 | 广州启妆生物科技有限公司 | Recombinant human collagen peptide and application thereof |
| CN112626074A (en) * | 2021-01-11 | 2021-04-09 | 肽源（广州）生物科技有限公司 | Hydroxyproline-modified recombinant human III-type collagen mature peptide and preparation method and application thereof |
| CN116284339A (en) * | 2022-12-29 | 2023-06-23 | 深圳柏垠生物科技有限公司 | Recombinant III type collagen, nucleic acid, expression vector, strain and application thereof |
| KR102581376B1 (en) * | 2022-10-25 | 2023-09-22 | 주식회사 에이바이오테크 | Collagen type 3 small-molecular peptide having collagen synthesis promoting activity and method using the same |
-
2023
- 2023-08-16 CN CN202311032714.6A patent/CN116874590B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110092835A (en) * | 2018-01-30 | 2019-08-06 | 上海惠盾生物技术有限公司 | A kind of GLP-1 analog-COL3A1 fusion protein |
| CN111944057A (en) * | 2020-07-23 | 2020-11-17 | 广州启妆生物科技有限公司 | Recombinant human collagen peptide and application thereof |
| CN112626074A (en) * | 2021-01-11 | 2021-04-09 | 肽源（广州）生物科技有限公司 | Hydroxyproline-modified recombinant human III-type collagen mature peptide and preparation method and application thereof |
| KR102581376B1 (en) * | 2022-10-25 | 2023-09-22 | 주식회사 에이바이오테크 | Collagen type 3 small-molecular peptide having collagen synthesis promoting activity and method using the same |
| CN116284339A (en) * | 2022-12-29 | 2023-06-23 | 深圳柏垠生物科技有限公司 | Recombinant III type collagen, nucleic acid, expression vector, strain and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| HELENA KUIVANIEMIA等: "Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases", GENE, 30 July 2019 (2019-07-30), pages 151 - 171 * |
| NCBI: "Homo sapiens collagen type III alpha 1 chain (COL3A1), mRNA", GENBANK DATABASE, pages 000090 * |
| 唐云平;郑强;胡斌;蔡谨;黄磊;徐志南;: "重组胶原蛋白制备及其应用研究进展", 食品工业科技, no. 18, 24 May 2016 (2016-05-24), pages 384 - 386 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117986355A (en) * | 2024-04-03 | 2024-05-07 | 江苏亨瑞生物医药科技有限公司 | Recombinant humanized III type collagen and preparation method and application thereof |
| CN117986355B (en) * | 2024-04-03 | 2024-06-11 | 江苏亨瑞生物医药科技有限公司 | Recombinant humanized III type collagen and preparation method and application thereof |
| CN118909094A (en) * | 2024-08-09 | 2024-11-08 | 上海兰之美雅化妆品有限公司 | Recombinant III type collagen Yves-Col3 with anti-aging effect and preparation method and application thereof |
| CN119431561A (en) * | 2025-01-13 | 2025-02-14 | 江苏亨瑞生物医药科技有限公司 | Method for fermenting and recombining humanized collagen by using escherichia coli and application of method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116874590B (en) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116874590B (en) | Recombinant III type collagen and preparation method thereof | |
| CN109593126B (en) | Polypeptide, its production method and purposes | |
| CN114805551B (en) | Recombinant type III collagen and preparation method thereof | |
| CN111944057B (en) | Recombinant human collagen peptide and application thereof | |
| CN110845603B (en) | Human collagen 17-type polypeptide, production method and use thereof | |
| CN116574172B (en) | Recombinant humanized type I collagen and preparation method thereof | |
| JP6906669B1 (en) | Recombinant fibronectin mutant, its preparation method and its use | |
| CN103122027A (en) | Recombinant human collagen and production method thereof | |
| CN115960209B (en) | Recombinant humanized collagen and application thereof | |
| CN117986355B (en) | Recombinant humanized III type collagen and preparation method and application thereof | |
| CN110950967B (en) | Anti-human serum albumin nano antibody and IL-2 fusion protein and preparation method thereof | |
| JPS62174026A (en) | Remedy for leukpenia | |
| CN111217903B (en) | Recombinant human fibronectin III 1-C and preparation method and application thereof | |
| CN112941081A (en) | Coding sequence of fibronectin mutant with high expression quantity and strong activity and application thereof | |
| WO2024119724A1 (en) | Collagen peptide, preparation method therefor and use thereof | |
| CN113735960A (en) | Application of FGF recombinant protein in treatment of NASH | |
| CN118221802A (en) | Recombinant XVII type collagen for promoting hair growth, and preparation method and application thereof | |
| CN116640231B (en) | Recombinant humanized 17-type collagen polypeptide and preparation method thereof | |
| CN115991763B (en) | Recombinant human III type collagen and preparation method and application thereof | |
| CN117820462B (en) | High-activity recombinant human fibronectin and preparation method and application thereof | |
| CN114409800B (en) | Method for preparing recombinant cystatin C | |
| CN118955692B (en) | A recombinant collagen with transdermal effect and its preparation method and application | |
| CN102559725A (en) | Human stem cell growth factor as well as production method and application of polyethylene glycol (PEG) modified human stem cell growth factor | |
| CN119552240A (en) | Recombinant humanized type I collagen based on expression and purification in escherichia coli and application thereof | |
| CN119431561A (en) | Method for fermenting and recombining humanized collagen by using escherichia coli and application of method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |